-
Differences in outcomes and responses to treatment in diverse populations often have been attributed to biological factors. However, standardized treatment can tell a divergent story, one in which parameters, such as geographic location and financial status, play a significant role in how a person responds. This underscores the importance of a diverse study population in clinical trials, researchers say.
-
Contemplating death can be uncomfortable, but by planning ahead, researchers can find peace in knowing their life’s work continues beyond their physical presence.
-
In an updated policy statement, the American Society for Reproductive Medicine says transgender status should not prevent a patient from accessing fertility preservation. Further, reproductive services should be offered to all interested transgender or nonbinary individuals, barring other disqualifying factors (based on empirical evidence as opposed to bias or stereotypes).
-
The MENDS2 trial found that dexmedetomidine, when used for light sedation, had outcomes similar to those for propofol.
-
A shorter program could be more useful for smaller universities that may not have the resources available to implement a longer program.
-
These two trials had disparate findings with respect to interleukin-6 inhibition, with REMAP-CAP showing a benefit and COVACTA showing none.
-
In this retrospective analysis of COVID-19 patients hospitalized with cytokine storm, the use of corticosteroids combined with tocilizumab was associated with superior survival when compared to no immunomodulatory treatment; a combination of corticosteroids and anakinra; or corticosteroids, tocilizumab, or anakinra alone. Patients who received corticosteroids, either alone or in combination with anakinra, also experienced lower hospital mortality compared to no treatment.
-
By including ordinary people, researchers could create consent forms, and a consenting process, that is primarily suited to meeting the needs of potential participants.
-
Keep in mind the person who has who to digest informed consent information. Avoiding complex terminology could lead to better understanding among the laypeople who participate in clinical trials.
-
Some ethicists are unaware of how code status options are named and defined at their institutions. Researchers found that at some hospitals, code status options in the electronic medical record did not even match what was in the hospital policy. Ethics should be one of the experts in this area.
